Company Overview
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Why Investors Should Care
Return on capital employed stands at 22.9%.
Net profit has compounded at 87.0% per year over the last five years.
Revenue has grown at a 16.1% CAGR over the past five years.
Trades at a P/E of 21.0, below the sector median of 25.4.
Carries low leverage with a debt-to-equity ratio of 0.07.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $418.63M (+20.0% YoY); net profit $48.58M.
- Trailing 12 Months Year-on-year growth — revenue -33.1%, earnings +14.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.1%, profit CAGR 87.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.05% |
| 1 Year: | -33.10% |
Compounded Profit Growth
| 5 Years: | 86.96% |
| 1 Year: | 14.52% |
Stock Price Performance
| 1 Year: | -38.24% |
| 6 Months: | -31.15% |
| 3 Months: | +7.14% |
| 1 Month: | +13.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)65.68 · Neutral
P/E of 21.00 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 22.9%.
- Compounding revenue at 16.1% over 5 years.
- Profit CAGR of 87.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 47.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDXG MiMedx Group, Inc. R2K | 4.20 | 21.00 | $625.57M | 0.00% | 22.95% | 13.77% | 16.05% | 86.96% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 68.80M | 80.49M | 84.00M | 87.86M | 84.15M | 95.42M | 86.96M | 92.59M | 66.56M | 67.44M | 88.86M | 76.40M | 61.74M | 53.65M | 64.30M | 68.55M | 59.97M | 68.17M | 63.07M | 58.89M | 66.88M | 67.69M | 71.68M | 81.26M | 81.71M | 84.71M | 87.21M | - | - | 88.20M | 98.61M | 113.72M | 118.09M | 58.99M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.56M | 18.68M | 18.72M | 19.05M | 17.37M |
| Gross Profit | 44.04M | 46.85M | 45.42M | 49.95M | 56.43M | 60.81M | 60.77M | 72.00M | 74.70M | 78.45M | 74.79M | 86.15M | 79.60M | 82.18M | 59.14M | 57.69M | 75.66M | 63.69M | 51.71M | 45.45M | 54.01M | 57.73M | 50.33M | 55.41M | 52.95M | 48.96M | 55.06M | 55.50M | 59.26M | 67.67M | 66.92M | 71.72M | 72.35M | - | - | 71.65M | 79.92M | 95.01M | 99.04M | 41.62M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.40M | 67.55M | 72.82M | 77.96M | 57.67M |
| Operating Income | 6.71M | - | 1.47M | 3.56M | 4.70M | - | 6.18M | 7.21M | 8.84M | - | 2.97M | 1.68M | 373.00K | - | -13.41M | -17.07M | 14.20M | - | -13.74M | -5.86M | -9.71M | - | -6.85M | -410.00K | -1.07M | -9.30M | -9.64M | -7.10M | -340.00K | 10.84M | 11.12M | 13.20M | 23.45M | - | - | 8.25M | 12.37M | 22.19M | 21.08M | -16.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.29M | 15.54M | 27.48M | 24.30M | -13.31M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -403.00K | 478.00K | - | - | - | 402.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.61M | 13.01M | 22.85M | 21.80M | -15.33M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.59M | 3.39M | 6.10M | 6.60M | -4.47M |
| Net Income | 6.55M | 13.38M | 1.20M | 1.98M | 3.32M | 5.48M | 6.00M | 10.40M | 44.05M | 4.28M | 4.62M | 1.80M | -178.00K | -36.22M | -13.27M | -17.21M | 12.38M | -7.48M | -4.82M | -8.47M | -19.42M | -16.58M | -8.38M | -1.78M | -2.34M | -10.49M | -10.87M | -8.43M | -4.98M | 1.20M | 8.53M | 9.26M | 17.62M | - | - | 7.02M | 9.62M | 16.75M | 15.19M | -10.86M |
| Diluted EPS | 0.06 | 0.11 | 0.01 | 0.02 | 0.03 | 0.05 | 0.05 | 0.09 | 0.37 | 0.04 | 0.04 | 0.02 | 0.00 | -0.34 | -0.12 | -0.16 | 0.11 | -0.07 | -0.04 | -0.08 | -0.48 | -0.17 | -0.09 | -0.03 | -0.04 | -0.11 | -0.11 | -0.09 | -0.06 | 0.01 | 0.06 | 0.06 | 0.12 | - | - | 0.05 | 0.06 | 0.11 | 0.10 | -0.07 |
| R&D Expense | 2.19M | - | 2.50M | 3.17M | 2.92M | - | 4.20M | 4.75M | 5.48M | - | 3.54M | 3.72M | 3.96M | - | 2.90M | 2.83M | 2.69M | - | 2.65M | 2.26M | 3.37M | - | 4.34M | 4.06M | 4.37M | 5.96M | 5.51M | 5.95M | 3.48M | 3.67M | 3.08M | 2.84M | 3.01M | 2.92M | - | 3.33M | 3.30M | 3.70M | - | 4.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 788.87K | 7.76M | 27.05M | 59.18M | 118.22M | 187.30M | 221.71M | 321.14M | 359.11M | 299.25M | 248.23M | - | 267.84M | 321.48M | 348.88M | 418.63M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 48.32M | 54.63M | 60.07M | 73.01M |
| Gross Profit | - | 4.40M | 21.86M | 49.85M | 105.56M | 167.09M | 190.77M | 285.92M | 322.73M | 256.17M | 208.90M | - | 219.53M | 266.84M | 288.81M | 345.62M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 234.25M | 229.73M | 229.50M | 281.73M |
| Operating Income | -10.53M | -9.76M | -5.36M | -2.64M | 7.10M | 24.36M | 884.00K | 46.22M | -3.92M | -21.16M | -45.40M | - | -14.73M | 37.12M | 59.31M | 63.89M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -10.69M | 40.54M | 65.35M | 78.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 4.98M | 5.02M | 6.46M | 1.01M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -19.75M | 30.63M | 57.29M | 66.26M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 206.00K | -36.81M | 15.30M | 17.68M |
| Net Income | -11.42M | -10.19M | -7.66M | -4.11M | 6.22M | 29.45M | 390.00K | 64.73M | -29.98M | -25.58M | -49.28M | - | -30.20M | 58.23M | 42.42M | 48.58M |
| Diluted EPS | - | - | -0.09 | -0.04 | 0.05 | 0.26 | 0.00 | 0.56 | -0.28 | -0.24 | -0.77 | - | -0.33 | 0.37 | 0.28 | 0.32 |
| R&D Expense | 2.75M | 2.98M | 2.88M | 4.84M | 7.05M | 8.41M | 14.34M | 17.90M | 15.77M | 11.14M | 11.71M | 9.93M | 12.70M | 12.66M | 12.34M | 15.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.35M | 27.10M | 35.18M | 84.69M | 109.26M | 135.91M | 117.27M | 121.25M | 122.84M | 167.17M | 202.03M | - | 171.43M | 239.05M | 263.92M | 342.65M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 134.20M | 164.26M | 191.89M | 277.47M |
| Cash & Equivalents | 2.65M | 1.34M | 4.11M | 6.75M | 44.08M | 46.58M | 26.30M | 30.32M | 27.48M | 45.12M | 69.07M | 95.81M | - | 65.95M | 82.00M | 104.42M | 166.12M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.18M | 21.02M | 23.81M | 25.34M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.08M | 53.87M | 55.83M | 75.71M |
| Total Liabilities | - | 1.25M | 15.20M | 15.18M | 11.13M | 19.93M | 27.93M | 69.21M | 47.46M | 73.19M | 132.77M | 110.61M | - | 189.42M | 96.33M | 70.81M | 86.11M |
| Current Liabilities | - | 1.25M | 4.73M | 5.02M | 9.61M | 18.40M | 26.78M | 60.79M | 45.81M | 71.55M | 67.32M | 59.16M | - | 43.56M | 46.01M | 45.59M | 64.27M |
| Long Term Debt | - | - | 2.74M | 4.01M | 0 | - | - | - | - | 0 | 61.91M | 47.70M | - | 48.59M | 48.10M | 17.83M | 16.47M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.59M | 49.10M | 18.83M | 17.97M |
| Total Equity | 6.07M | 6.10M | 11.90M | 20.01M | 73.57M | 89.33M | 34.72M | 48.07M | 73.80M | 49.66M | 34.40M | -150.00K | - | -17.99M | 142.72M | 193.11M | 256.55M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 113.71M | 146.23M | 146.93M | 148.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.16M | -6.66M | -3.33M | -284.00K | 16.80M | 18.81M | 23.85M | 62.94M | 35.80M | -39.41M | -30.26M | -1.98M | -17.89M | 26.77M | 66.20M | 74.00M |
| Investing Cash Flow | -151.62K | -702.51K | -637.00K | -3.03M | -12.15M | -678.00K | -11.68M | -5.40M | -9.22M | 504.00K | -4.55M | -3.40M | -2.66M | -2.15M | -9.58M | -6.89M |
| Financing Cash Flow | 7.00M | 10.14M | 6.61M | 40.63M | -2.15M | -36.23M | -8.15M | -60.39M | -8.93M | 62.86M | 61.56M | -3.35M | -580.00K | -8.57M | -34.20M | -5.41M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | -3.22M | -1.51M | -1.99M | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | -5.20M | -19.41M | 24.79M | - | - |
| Share Buybacks | - | - | - | - | - | 40.14M | 10.40M | 68.30M | 7.60M | - | 900.00K | 0 | 0 | 9.52M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 56.7% | 80.8% | 84.2% | 89.3% | 89.2% | 86.0% | 89.0% | 89.9% | 85.6% | 84.2% | - | 82.0% | 83.0% | 82.8% | 82.6% |
| Operating Margin % | -1,335.2% | -125.8% | -19.8% | -4.5% | 6.0% | 13.0% | 0.4% | 14.4% | -1.1% | -7.1% | -18.3% | - | -5.5% | 11.5% | 17.0% | 15.3% |
| Net Margin % | -1,447.6% | -131.4% | -28.3% | -6.9% | 5.3% | 15.7% | 0.2% | 20.2% | -8.3% | -8.5% | -19.9% | - | -11.3% | 18.1% | 12.2% | 11.6% |
| ROE % | -187.2% | -85.7% | -38.3% | -5.6% | 7.0% | 84.8% | 0.8% | 87.7% | -60.4% | -74.4% | 32,856.0% | - | 167.9% | 40.8% | 22.0% | 18.9% |
| ROCE % | -172.7% | -43.6% | -17.8% | -3.5% | 7.8% | 22.3% | 1.6% | 61.3% | -7.6% | -21.2% | -31.8% | - | -11.5% | 19.2% | 27.2% | 22.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Essex Woodlands Management Inc. | 25.56% | 28.20M | $112.08M |
| 2 | Blackrock Inc. | 10.80% | 11.91M | $47.35M |
| 3 | Trigran Investments Inc | 6.51% | 7.18M | $28.52M |
| 4 | Vanguard Capital Management LLC | 4.68% | 5.17M | $20.53M |
| 5 | State Street Corporation | 4.58% | 5.06M | $20.10M |
| 6 | Paradigm Capital Management | 3.09% | 3.41M | $13.56M |
| 7 | Nantahala Capital Management, LLC | 3.08% | 3.40M | $13.50M |
| 8 | Renaissance Technologies, LLC | 2.74% | 3.02M | $12.00M |
| 9 | Geode Capital Management, LLC | 2.61% | 2.88M | $11.45M |
| 10 | First Light Asset Management, LLC | 2.58% | 2.84M | $11.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDXG
MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOYW5EQi1SeTdPWjgxNHpQbU1fZWw3WXpmbWpHN2hCOWx3ckdMcDZqOHlhVnFYWExUYXBTaU1jbU93U29sNkZiUTBXbGFrVVNxdTZQVHJqdkYxTlpZbkNNY05IZllpRFZweDQwY2xPRXB2d1JRNVdHVWNzb1NvLVFWOXk5OHVuSVdoVFJ2MG…
MDXG Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBlRFduRC1iMk9zRUxXd19GZG1obFFFNW0wNUdhWXF0bUh2ZzlGOF96NzNyQWJJb2xmQ1B5VXlPUjEzOWRKUDBUNzZDWWhoT2NralJiOVZQZHJCTDJEUE5lV0tYLTByemlxbDNZNGJDWFhzeFZPa1g3NVFR?oc=5" target="_blank">MDX…
MIMEDX (MDXG) CFO has shares withheld to cover RSU tax liability - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOT2o1WmdyZzBPbUpsV0ZsSWZBb1BzRFdOdktfekJLYU5OeF9BRjVOS1UwS2QtVzgtOW1MUW1fWTh5X05jWDAzTWRqOGxwcU5ESFBDTU5XbVAtZ3BWNmd6MnlINWF2TVBGbVB6UXQxMU4wUFF5RHNnOXVPYlhiaDFkLVBnaF9tZEVqclE2Un…
MiMedx: The Hard Math Behind My Downgrade To Hold - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNT0JqSUdfNTB5WlJBZUNWd0RHRy1wZlhyNmhYaHZmZ2xybDJWdi11OGtGSXYxeXBrSTYxMzlWekVkQzFDM2V0V2xuOXF0NXN1MExGaF8ySThnNkpPd0JJd05DMUQ1d0tmM0N1Y0RkVkpaZi1sY3REb3JPR1lQTWxUQlZyNWdMaEMzNVBKWn…
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNWGhseDNYZEZjNlREQnFYeWs0ZFBSLWhRRURJWmR3UjNkdEdTampMS2pNZmZsQXlQR3oyZ082UFNudjRLMUZWdy1YRVk3U0RRS0pHM0hSSzVhdkxSUmpudnRwUnIwaUhWS3hOOGduNHNOZEIxYUwtekZlUE1yZEZWTndoZ3l3a2szRUlBZ2…
How The MiMedx Group (MDXG) Investment Story Is Shifting On Reimbursement Risk And Recovery Hopes - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxOUVVXVUU4U0JyMXMxYmpxUi11MzBIcFRLUW9xR1E4ckRUUEN4Y3FUMG44aFQzZlJNcWkyU2Jaa1BjWmlZY1lkYzVlbW5WSzZ1WVNyNGM3Y3ktbmY1NWZieHAtOTNPTUtTN1ZsdnFuQ0t6bE1WeHNJS3UzYi1WUTRTc2F0V0RuYW8?oc=5" …
MDXG — Frequently Asked Questions
What is the current share price of MiMedx Group, Inc. (MDXG)?
As of 2026-07-14 21:23 PDT, MiMedx Group, Inc. (MDXG) trades at $4.20 on NasdaqCM. Its 52-week range is $3.09 to $7.96.
What is the market capitalisation of MDXG?
MiMedx Group, Inc. (MDXG) has a market capitalisation of $625.57M on NasdaqCM.
What is the P/E ratio of MDXG?
MDXG trades at a trailing price-to-earnings (P/E) ratio of 21.00. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.08.
What is the return on equity (ROE) of MDXG?
MDXG has a return on equity (ROE) of 13.77%. Its return on capital employed (ROCE) is 22.95%.
Is MDXG a good stock to buy?
This page provides a data-driven analysis of MiMedx Group, Inc. (MDXG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.